实体器官移植后HLA抗原错配与皮肤癌发生风险的关联
本研究为多中心移植皮肤癌网络研究的回顾性队列二次分析,纳入2003年或2008年接受首次实体器官移植的10649名成人,随访59923人年。每增加一个错配等位基因,皮肤癌风险降低7%至8%(校正HR 0.93,95%CI 0.87-0.99,P=0.01);肺和心脏移植受者中保护作用有统计学意义,肝、肾、胰腺移植受者中未见。
要点
- 每增加一个HLA错配等位基因,皮肤癌风险降低7%至8%(校正HR 0.93,95%CI 0.87-0.99,P=0.01)。
- 肺移植(校正HR 0.70,95%CI 0.56-0.87,P=0.001)和心脏移植(校正HR 0.75,95%CI 0.60-0.93,P=0.008)受者中保护作用有统计学意义。
- HLA-DR错配程度与皮肤癌风险的关联最具统计学意义(校正HR 0.85,95%CI 0.74-0.97,P=0.01),HLA-A或HLA-B错配未见。
核心结论
- HLA抗原错配似乎与心脏和肺移植受者实体器官移植后皮肤癌风险降低相关。
- 作者认为该发现提示HLA抗原错配激活了针对皮肤癌的肿瘤监视机制,配型良好器官的受者皮肤癌风险可能更高。
研究设计与样本
- 多中心移植皮肤癌网络研究的回顾性队列二次分析。
- 纳入2003年1月1日至2003年12月31日或2008年1月1日至2008年12月31日接受首次实体器官移植的10649名成人。
- 参与者经移植受者科学登记处标准分析文件识别,数据主要由器官获取与移植网络收集,并通过病历回顾匹配皮肤癌结局。
- 研究实施时间为2016年8月1日至2017年7月31日。
- HLA抗原错配按2016年器官获取与移植网络指南计算,采用多因素Cox比例风险回归模型分析。
主要发现
- 共10649名器官移植受者(6776名男性[63.6%],平均[SD]年龄51[12]岁),贡献59923人年随访。
- 每增加一个错配等位基因,皮肤癌风险降低7%至8%(校正HR 0.93,95%CI 0.87-0.99,P=0.01)。
- 亚组分析中HLA抗原错配的保护作用在肺移植(校正HR 0.70,95%CI 0.56-0.87,P=0.001)和心脏移植(校正HR 0.75,95%CI 0.60-0.93,P=0.008)受者中有统计学意义,肝、肾、胰腺移植受者中未见。
- HLA-DR错配程度与皮肤癌风险的关联最具统计学意义(校正HR 0.85,95%CI 0.74-0.97,P=0.01),HLA-A或HLA-B错配未见。
- 主要结局为移植后皮肤癌诊断时间,包括鳞状细胞癌、黑色素瘤和梅克尔细胞癌。
临床怎么用
- 作者认为HLA抗原错配似乎与心脏和肺移植受者移植后皮肤癌风险降低相关。
- 作者认为该发现提示HLA抗原错配激活针对皮肤癌的肿瘤监视机制,配型良好器官的受者皮肤癌风险可能更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Risk factors for the development of skin cancer after solid-organ transplant can inform clinical care, but data on these risk factors are limited. OBJECTIVE: To study the association between HLA antigen mismatch and skin cancer incidence after solid-organ transplant. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study is a secondary analysis of the multicenter Transplant Skin Cancer Network study of 10 649 adults who underwent a primary solid-organ transplant between January 1, 2003, and December 31, 2003, or between January 1, 2008, and December 31, 2008. These participants were identified through the Scientific Registry of Transplant Recipients standard analysis files, which contain data collected mostly by the Organ Procurement and Transplantation Network. Participants were matched to skin cancer outcomes by medical record review. This study was conducted from August 1, 2016, to July 31, 2017. MAIN OUTCOMES AND MEASURES: The primary outcome was time to diagnosis of posttransplant skin cancer, including squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The HLA antigen mismatch was calculated based on the 2016 Organ Procurement and Transplantation Network guidelines. Risk of skin cancer was analyzed using a multivariate Cox proportional hazards regression model. RESULTS: In total, 10 649 organ transplant recipients (6776 men [63.6%], with a mean [SD] age of 51 [12] years) contributed 59 923 years of follow-up. For each additional mismatched allele, a 7% to 8% reduction in skin cancer risk was found (adjusted hazard ratio [HR], 0.93; 95% CI, 0.87-0.99; P = .01). Subgroup analysis found the protective effect of HLA antigen mismatch to be statistically significant in lung (adjusted HR, 0.70; 95% CI, 0.56-0.87; P = .001) and heart (adjusted HR, 0.75; 95% CI, 0.60-0.93; P = .008) transplant recipients but not for recipients of liver, kidney, or pancreas. The degree of HLA-DR mismatch, but not HLA-A or HLA-B mismatch, was the most statistically significant for skin cancer risk (adjusted HR, 0.85; 95% CI, 0.74-0.97; P = .01). CONCLUSIONS AND RELEVANCE: The HLA antigen mismatch appears to be associated with reductions in the risk of skin cancer after solid-organ transplant among heart and lung transplant recipients; this finding suggests that HLA antigen mismatch activates the tumor surveillance mechanisms that protect against skin cancer in transplant recipients and that skin cancer risk may be higher in patients who received a well-matched organ.
引用
- Gao Y, Twigg AR, Hirose R, et al. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant. JAMA Dermatol. 2019. PMID: 30673077. doi:10.1001/jamadermatol.2018.4983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。